Skip to main content
. 2019 Oct 25;10:2514. doi: 10.3389/fimmu.2019.02514

Figure 7.

Figure 7

Treatment of ex vivo cells derived from ovarian cancer patients. (A) Primary ovarian carcinoma cytotoxicity assay after 4 and 16 h of treatment with TRAIL-R2xCD3 or Mec14xCD3 scDbs and pre-activated healthy donors' PBLs. 09ST and 10ST: short-term ovarian cancer cell lines established from biopsies; 13A, 15A, and 16A: cells isolated from ascitic fluid of ovarian cancer patients. The graphs show the percentage of direct cell lysis as the mean ± SD of three wells for treatment. Statistical analysis by one-way ANOVA followed by Tukey's post-test. ***p < 0.001; ns: not significant. (B) Representative staining for CD45 and EpCAM (left) and TRAIL-R2 expression in EpCAM+ tumor cells (right) in an ascitic fluid from an ovarian cancer patient. (C) Flow cytometry expression of the surface activation markers CD107a and CD137 on CD8+ (left) and CD4+ (right) T lymphocytes of ascites samples from three ovarian cancer patients, treated or not with scDb (0.5 μg/mL, 18 h). (D) Annexin-V/propidium iodide apoptosis assay of tumor cells (EpCAM+/CD45−) treated or not with 0.5 μg/mL scDb for 48 h. Statistical analysis by Student T-test. *p < 0.05. (E) Annexin-V/propidium iodide apoptosis assay on CD8+ T cells treated as in (D).